Freedom Broker upgraded Atara Biotherapeutics (ATRA) to Hold from Sell with a price target of $10, up from $4. The FDA meeting between Pierre Fabre and the FDA ended on a positive note for Atara, with the parties agreeing on the design of a new filing for tab-cel, the analyst tells investors in a research note. Freedom now views the probability of U.S. approval as high.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Manufacturing and Supply-Chain Risks Threaten Atara Biotherapeutics’ Cell Therapy Pipeline
- Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c
- HubSpot, Atara, Upwork, Fastly, Planet Fitness Trending With Analysts
- Atara Biotherapeutics upgraded to Buy from Hold at Canaccord
- Atara Biotherapeutics trading halted, volatility trading pause